Brazil · Medical and donor conditions

Editorial illustration of a reproductive-medicine consent checklist, specimen container and microscope behind glass.

Brazil: Medical and Gamete-Donor Requirements for Gestational Surrogacy

Short answer

In Brazil, a clinic’s availability alone does not establish eligibility for gestational substitution. Before transfer, the clinical file must support a medical indication, the carrier’s eligibility, informed consent and required commitments. Donor gametes have separate age, clinical/laboratory screening, confidentiality and traceability rules. The main instruments checked here are CFM Resolution No. 2,320/2022 and ANVISA RDC No. 771/2022.

The CFM resolution is a professional ethical standard for Brazilian physicians; ANVISA’s RDC sets sanitary requirements for assisted-reproduction centres and reproductive material. Neither alone resolves parentage, contract enforceability, nationality or foreign recognition. This guide addresses medical and donor requirements only.

Which rules control?

CFM Resolution No. 2,320/2022 is the principal professional rule for the clinical decisions below. The resolution describes itself as the deontological standard to be followed by Brazilian physicians; the official materials do not establish whether any subsequent formal act has been adopted. It addresses when assisted reproduction may be used, the conditions for gestational substitution, donor age and identity, and required records. A breach may raise professional-discipline issues, but does not automatically establish that every private agreement is void.

ANVISA RDC No. 771/2022 sets minimum sanitary and technical requirements for public and private assisted-reproduction centres (CRHAs), including donor screening, testing, consent, sample segregation, records and traceability. Bill PL 1,260/2026, proposing a broader framework, remained pending in the Chamber of Deputies on 26 October 2026. A bill is not law. The CFM plenary agenda for August 2026 included a proposal to open a review concerning embryo-disposal rules; an agenda item does not amend the resolution.

Requirements at a glance

TopicRegulatory baselineSource / point to verify
Carrier indicationA medical condition prevents or contraindicates pregnancy; success and serious-risk criteria apply.CFM 2,320/2022; individual assessment.
Carrier eligibilityAt least one living child and blood kinship to fourth degree; otherwise seek CRM authorization.CFM rule; no automatic exception.
Payment and selectionNo profit/commercial character; clinic cannot intermediate selection.CFM professional rule; review expenses separately.
Donor ageCivil majority; women up to 37, men up to 45; limited female exceptions.CFM 2,320/2022; ANVISA RDC 771/2022.
Donor testsClinical interview, consent, infectious/genetic tests, timing and sample controls.ANVISA RDC 771/2022; panels differ by material.
Identity and paymentConfidentiality by default; narrow family exception; donation unpaid.CFM and ANVISA; exceptions are limited.
Records and transferHealth report and commitments; transfer limits and no embryo reduction in multiple pregnancy.CFM 2,320/2022; verify before cycle.

Medical indication and health risk

CFM permits gestational substitution through assisted-reproduction techniques where a condition prevents or contraindicates pregnancy. This is a medical indication, not simply a preference for someone else to carry the pregnancy. The general CFM rule also requires a realistic possibility of success and a low probability of serious risk to the patient or possible child. The responsible clinician must assess the actual medical history and explain material risks; the regulation does not guarantee that a cycle will be approved or succeed.

The CFM sets a general maximum age of 50 for women undergoing pregnancy through assisted-reproduction techniques. An exception may be accepted only on a reasoned technical and scientific basis from the responsible physician, addressing the absence of comorbidities unrelated to infertility and explaining risks to the patient and potential offspring. Because the text states a general rule for candidates for pregnancy, the clinic and relevant CRM should confirm how it applies to the proposed carrier and any exception in the specific case.

Gestational carrier: eligibility and prohibitions

The carrier must have at least one living child and be a blood relative of one intended parent or partner up to the fourth degree. CFM examples are parents/children (first degree), grandparents/siblings (second), aunts/uncles and nieces/nephews (third), and cousins (fourth). Friendship and everyone’s agreement do not replace the default kinship rule.

If the family relationship requirement cannot be met, the CFM resolution requires an application for authorization to the relevant Regional Council of Medicine (CRM). This is not an automatic exception. Confirm which CRM is competent and what evidence it requires; as a safe step, obtain the CRM’s written decision before treatment and have Brazilian counsel confirm the applicable procedure. The arrangement may not be for profit or commercial in character, and the clinic may not intermediate carrier selection. The rule does not settle every expense-reimbursement question; obtain case-specific advice.

The person carrying the pregnancy cannot also be the oocyte or embryo donor in that same arrangement. If eggs are needed from a donor, the donor and carrier must be different people. This separation is explicit in the CFM rules and should be reflected in the clinical file and consent documents.

Required medical and consent file

The CFM resolution says the following must be recorded in the patient’s file at the assisted-reproduction clinic. Treat these as items to obtain in writing, not as optional clinic paperwork:

  • Informed-consent form signed by the intended parent(s) and the carrier, covering biopsychosocial issues, pregnancy and puerperium risks, and legal aspects of filiation.
  • A medical report stating that the physical and mental health of all involved is adequate.
  • A written commitment between the intended parent(s) and carrier clearly addressing the child’s filiation.
  • A commitment by the intended parent(s) to provide the carrier with medical care and, where needed, multidisciplinary follow-up through the puerperium, in both public and private services.
  • A commitment by the intended parent(s) to arrange the child’s civil registration; the related documentation must be prepared during pregnancy.
  • Written approval from the carrier’s spouse or partner if she is married or lives in a stable union.

Gamete donors: age and role separation

A gamete or embryo donor must have reached civil majority, agree to the required infectious-disease and, where applicable, genetic tests, complete the clinical-screening interview and sign a specific informed-consent form. Under CFM Resolution No. 2,320/2022, the age limits are 37 years for a woman donating oocytes and 45 years for a man donating sperm. For donated oocytes, the relevant age is the donor’s age when the oocytes were collected, not her age when the recipient later uses them.

The CFM allows exceptions to the female age limit for oocytes frozen earlier, embryos frozen earlier, and qualifying family donation to a recipient’s relative up to the fourth degree, subject to the resolution’s conditions and adequate explanation of risks to the recipient(s). The rule does not set a parallel age exception for male donors. Do not turn these narrow exceptions into a general waiver of donor-age limits.

Mandatory donor assessment

ANVISA RDC No. 771/2022 requires donor assessment before a donation can proceed. At minimum, the candidate must be an adult, agree to the infectious-marker tests specified by the RDC, agree to genetic-mutation tests where applicable, sign informed consent and undergo a clinical interview. A trained and qualified higher-education professional must administer the donor-screening questionnaire. The interview must consider debilitating physical or mental conditions, serious disease, genetic disease and other clinical circumstances that may contraindicate donation under the centre’s protocols.

Additional clinical or laboratory assessment may be necessary because of travel history or residence in an area with high local transmission of an infectious agent. The centre remains responsible for the screening process even where it contracts a qualified provider to perform part of it. The RDC also requires traceable records and does not allow rapid tests to be used for the laboratory screening of donors. Ask for the actual results and dates, not merely a statement that “all tests are clear.”

Laboratory screening: semen and oocytes

For sperm donors, RDC 771/2022 lists tests for HIV-1/2, hepatitis B and C, syphilis, HTLV-I/II, Zika, gonorrhoea, chlamydia, karyotype and sickle-cell trait. Blood and urine are collected on the semen-sampling date; if semen is collected over several days, they are collected on the final day. HIV, hepatitis B and C tests must be repeated at least 180 days after collection, and semen remains segregated and unreleased until retesting. No quarantine/retest is needed if initial tests for those three viruses are done simultaneously by serology and nucleic-acid testing (NAT).

For oocytes intended for cryopreservation, the panel includes HIV-1/2, hepatitis B and C, syphilis, Zika, gonorrhoea, chlamydia, karyotype and sickle-cell trait. Blood and urine must be collected within 30 days before retrieval. HIV and hepatitis B/C tests are repeated at least 180 days later; oocytes remain segregated and unreleased until then unless the RDC’s simultaneous-serology-and-NAT exception applies. Fresh oocyte donation additionally requires NAT for HIV, hepatitis B and C, with samples collected within 30 days before retrieval.

Under RDC art. 96, positive HIV, hepatitis B/C or HTLV results and an abnormal karyotype or sickle-cell-trait result for a sperm donor are grounds for permanent exclusion; positive syphilis, Zika, gonorrhoea or chlamydia results are grounds for temporary exclusion. Under arts. 97–98, for both cryopreserved and fresh oocytes, positive HIV, hepatitis B or C results and an abnormal karyotype or sickle-cell-trait result are grounds for permanent exclusion, while positive syphilis, Zika, gonorrhoea or chlamydia results are grounds for temporary exclusion. A temporary exclusion means donation cannot proceed until the required negative result is documented. Separately, art. 93 provides a narrowly controlled exceptional-release route for therapeutic use of samples with detected genetic alterations other than the listed donor-exclusion criteria. It requires a genetic-risk assessment approved by the originating centre’s medical lead, a medical report, specific informed consent and a dedicated written procedure. This is not a general waiver of the donor-exclusion criteria for karyotype abnormalities or sickle-cell trait. Ask the clinic to identify the exact provision and document the sample’s status.

Anonymity, records and compensation

Gamete and embryo donation must be gratuitous. CFM permits shared oocyte donation, where donor and recipient share biological material and procedure costs; this is not permission to sell eggs or pay a purchase price. The clinic should document the basis and cost allocation. Physicians, clinic employees and other members of the clinic’s multidisciplinary team may not be donors in assisted-reproduction programmes.

Donor and recipient identities are confidential by default. CFM permits a family-donation exception for a recipient’s relative up to the fourth degree, subject to a consanguinity proviso that needs specialist interpretation. ANVISA also requires strict confidentiality; sanitary authorities may inspect records, and special medical/legal information may be supplied to the treating physician while protecting civil identity. Centres must retain general clinical and phenotypic data and traceability.

CFM uses local birth records to avoid one donor causing more than two births of children of different sexes in an area of one million inhabitants. If the same recipient family chooses the same donor, the donor may contribute to as many pregnancies as that family wishes. Ask how the clinic applies this rule locally.

Embryo-transfer limits that affect clinical planning

The CFM’s general assisted-reproduction rule limits the number of embryos transferred according to age: women up to and including 37 may have up to two embryos transferred; women older than 37 may have up to three. Where embryos are euploid on genetic diagnosis, the limit is up to two regardless of age. In oocyte donation, the donor’s age at collection is used for this calculation. The CFM prohibits procedures intended to reduce embryos in a multiple pregnancy resulting from assisted reproduction. These are clinical safety limits, not a substitute for reviewing the individual patient’s risk profile.

What a clinic may add—and what it cannot waive

A clinic may use written protocols for extra assessments, such as risk-based infection tests, genetic counselling or a fuller psychosocial assessment. ANVISA itself contemplates protocol-based screening and additional tests where local risk warrants them. More than the minimum list may be requested if the medical or sanitary reason is explained.

An internal clinic policy is not a nationwide legal rule and cannot waive mandatory CFM or ANVISA requirements. Ask whether each item is a CFM rule, ANVISA sanitary rule, CRM approval condition or clinic protocol. Request the provision, test-validity period, consequence of a positive result and whether an exception needs written approval.

Before authorizing a cycle: checklist

Before signing or paying for a cycle, obtain written answers to these points:

  • Ask the clinic for the written medical indication and a risk assessment for the carrier and possible child.
  • Confirm the carrier has at least one living child and document the degree of consanguinity; if the family condition cannot be met, obtain the relevant CRM authorization before treatment.
  • Collect the signed consents, health report, filiation commitment, care-through-puerperium commitment, registration commitment and any required spouse/partner approval.
  • Confirm donor age at the legally relevant time, whether any female-age exception applies, and that the carrier is not also the oocyte/embryo donor.
  • Obtain the laboratory screening panel, dates, repeat-test plan, release/quarantine status and any genetic-risk explanation in writing.
  • Ask for the clinic’s written rule on costs, anonymity, recordkeeping and any additional tests; separate its policy from CFM, ANVISA and CRM requirements.

What this guide does not decide

These medical and donor rules do not by themselves determine legal parentage, enforceability of a private agreement, birth registration, the child’s nationality or recognition abroad. Those questions require separate Brazilian family-law and destination-country analysis. The no-commercial-character rule for gestational substitution and the no-remuneration rule for gamete donation concern related but distinct arrangements.

Primary and official sources

Last updated:

Author: Khachatrian Razmik, LL.M.

International surrogacy and parentage legal services — LEX SURROGACY by Lex Agency · Author profile · Editorial standards